keyword
MENU ▼
Read by QxMD icon Read
search

non-alcoholic steatohepatitis AND (treatment or therapy)

keyword
https://www.readbyqxmd.com/read/28212301/the-phytocomplex-from-fucus-vesiculosus-and-ascophyllum-nodosum-controls-postprandial-plasma-glucose-levels-an-in-vitro-and-in-vivo-study-in-a-mouse-model-of-nash
#1
Daniela Gabbia, Stefano Dall'Acqua, Iole Maria Di Gangi, Sara Bogialli, Valentina Caputi, Laura Albertoni, Ilaria Marsilio, Nicola Paccagnella, Maria Carrara, Maria Cecilia Giron, Sara De Martin
Edible seaweeds have been consumed by Asian coastal communities since ancient times. Fucus vesiculosus and Ascophyllum nodosum extracts have been traditionally used for the treatment of obesity and several gastrointestinal diseases. We evaluated the ability of extracts obtained from these algae to inhibit the digestive enzymes α-amylase and α-glucosidase in vitro, and control postprandial plasma glucose levels in a mouse model of non-alcoholic steatohepatitis (NASH); a liver disease often preceding the development of Type 2 diabetes (T2DM)...
February 15, 2017: Marine Drugs
https://www.readbyqxmd.com/read/28209193/up601-a-standardized-botanical-composition-composed-of-morus-alba-yerba-mate-and-magnolia-officinalis-for-weight-loss
#2
Mesfin Yimam, Ping Jiao, Mei Hong, Lidia Brownell, Young-Chul Lee, Eu-Jin Hyun, Hyun-Jin Kim, Jeong-Bum Nam, Mi-Ran Kim, Qi Jia
BACKGROUND: The prevalence of obesity is surging in an alarming rate all over the world. Pharmaceutical drugs are considered potential adjunctive therapy to lifestyle modification. However, for most, besides being too expensive, their long term usages are hindered by their severe adverse effects. Here we describe the effect of UP601, a standardized blend of extracts from Morus alba, Yerba mate and Magnolia officinalis, in modulating a number of obesity-related phenotypic and biochemical markers in a high-fat high-fructose (HFF)-induced C57BL/6J mouse model of obesity...
February 16, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28202906/bar502-a-dual-fxr-and-gpbar1-agonist-promotes-browning-of-white-adipose-tissue-and-reverses-liver-steatosis-and-fibrosis
#3
Adriana Carino, Sabrina Cipriani, Silvia Marchianò, Michele Biagioli, Chiara Santorelli, Annibale Donini, Angela Zampella, Maria Chiara Monti, Stefano Fiorucci
Non-alcoholic steatohepatitis (NASH) is a highly prevalent chronic liver disease. Here, we have investigated whether BAR502, a non-bile acid, steroidal dual ligand for FXR and GPBAR1, reverses steato-hepatitis in mice fed a high fat diet (HFD) and fructose. After 9 week, mice on HFD gained ≈30% of b.w (P < 0.01 versus naïve) and were insulin resistant. These overweighting and insulin resistant mice were randomized to receive HFD or HFD in combination with BAR502. After 18 weeks, HFD mice developed NASH like features with severe steato-hepatitis and fibrosis, increased hepatic content of triacylglycerol and cholesterol and expression of SREPB1c, FAS, ApoC2, PPARα and γ, α-SMA, α1 collagen and MCP1 mRNAs...
February 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28192190/%C3%AE-7-integrin-and-madcam-1-play-opposing-roles-during-the-development-of-non-alcoholic-steatohepatitis
#4
Hannah K Drescher, Angela Schippers, Thomas Clahsen, Hacer Sahin, Heidi Noels, Mathias Hornef, Norbert Wagner, Christian Trautwein, Konrad L Streetz, Daniela C Kroy
BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease in western countries. It is unclear how infiltrating leukocytes affect NASH-development. Hence our study aims to investigate the role of the homing/receptor-pair mucosal addressin cell adhesion molecule-1 (MAdCAM-1)/β7-Integrin for immune cell recruitment and disease progression in a steatohepatitis model. METHODS: Constitutive β7-Integrin deficient (β7(-/-)) and MAdCAM-1 deficient (MAdCAM-1(-/-)) mice were fed high-fat-diet (HFD) for 26 weeks or methionine-choline-deficient-diet (MCD) for 4 weeks...
February 9, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28190475/calycosin-attenuates-triglyceride-accumulation-and-hepatic-fibrosis-in-murine-model-of-non-alcoholic-steatohepatitis-via-activating-farnesoid-x-receptor
#5
Xingping Duan, Qiang Meng, Changyuan Wang, Zhihao Liu, Qi Liu, Huijun Sun, Pengyuan Sun, Xiaobo Yang, Xiaokui Huo, Jinyong Peng, Kexin Liu
BACKGROUND: Non-alcoholic steatohepatitis (NASH) represents the more severe end of hepatic steatosis and is associated with progressive liver disease. Calycosin, derived from the root of Radix Astragali, has been demonstrated to have favorable efficacy on acute liver injury. PURPOSE: The present study was to investigate the hepatoprotective effect of calycosin on attenuating triglyceride accumulation and hepatic fibrosis, as well as explore the potential mechanism in murine model of NASH...
February 15, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/28184028/long-term-administration-of-tacrolimus-and-everolimus-prevents-high-cholesterol-high-fructose-induced-steatosis-in-c57bl-6j-mice-by-inhibiting-de-novo-lipogenesis
#6
Sharma Love, Malik A Mudasir, Subhash C Bhardwaj, Gurdarshan Singh, Sheikh A Tasduq
AIM: To investigate the effects of tacrolimus (TC) and everolimus (EV) on non-alcoholic steatohepatitis (NASH) induced by high fat, high cholesterol and fructose (fast food) diet in C57BL/6J mice. MATERIALS AND METHODS: C57BL/6J mice were divided into four groups (n=8). 1) Standard Chow (SC); 2) Fast food (FF) diet; 3) FF + Tacrolimus (TC, 1mg/kg) and; 4) FF + Everolimus (EV, 1mg/kg) and treated for 16 weeks. Serum and tissue samples were analyzed for evidence of inflammation, fibrosis, lipogenesis, and apoptosis...
February 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28182612/non-alcoholic-fatty-liver-disease-in-hiv-infection
#7
Juan Macías, Juan A Pineda, Luis M Real
Non-alcoholic fatty liver disease is one of the most frequent chronic hepatic conditions worldwide. The spectrum of non-alcoholic fatty liver disease goes from hepatic steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Risk factors for non-alcoholic fatty liver disease are metabolic, mainly obesity and the accompanying consequences. Treatment and prevention of non-alcoholic fatty liver disease should target those metabolic abnormalities. The frequency of and the factors associated with hepatic steatosis in HIV infection seem to be similar to those reported in the general population, though direct comparisons are lacking...
January 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28177750/modulatory-role-of-co-enzyme-q10-on-methionine-and-choline-deficient-diet-induced-non-alcoholic-steatohepatitis-nash-in-albino-rats
#8
Dalia O Saleh, Rania F Ahmed, Mohamed M Amin
The present study aimed to evaluate the hepato-protective and neuro-protective activity of Co-enzyme Q10 (CoQ10) on non-alcoholic steatohepatitis (NASH) in albino rats induced by methionine and choline-deficient (MCD) diet. Rats were fed an MCD diet for 8 weeks to induce non-alcoholic steatohepatitis. CoQ10 (10 mg/(kg·day)(-1)) was orally administered for 2 consecutive weeks. Twenty-four hours after the last dose of the drug, the behavioral test, namely the activity cage test, was performed and the activity counts were recorded...
November 9, 2016: Applied Physiology, Nutrition, and Metabolism, Physiologie Appliquée, Nutrition et Métabolisme
https://www.readbyqxmd.com/read/28167322/-nlrp3-inflammasome-blockade-reduces-liver-inflammation-and-fibrosis-in-experimental-nash-in-mice
#9
Auvro R Mridha, Alexander Wree, Avril A B Robertson, Matthew M Yeh, Casey D Johnson, Derrick M Van Rooyen, Fahrettin Haczeyni, Narci C-H Teoh, Christopher Savard, George N Ioannou, Seth L Masters, Kate Schroder, Matthew A Cooper, Ariel E Feldstein, Geoffrey C Farrell
BACKGROUND AND AIMS: NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in NAFLD. We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. METHODS: We fed foz/foz and wildtype (Wt) mice atherogenic diet 16 weeks, gavaged MCC950 or vehicle until 24 weeks, then determining NAFLD phenotype. In mice fed methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle 6 weeks and determined effects on liver fibrosis...
February 3, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28154266/the-serum-oxidative-anti-oxidative-stress-balance-becomes-dysregulated-in-patients-with-non-alcoholic-steatohepatitis-associated-with-hepatocellular-carcinoma
#10
Yasuyuki Shimomura, Akinobu Takaki, Nozomu Wada, Tetsuya Yasunaka, Fusao Ikeda, Takayuki Maruyama, Naofumi Tamaki, Daisuke Uchida, Hideki Onishi, Kenji Kuwaki, Shinichiro Nakamura, Kazuhiro Nouso, Yasuhiro Miyake, Kazuko Koike, Takaaki Tomofuji, Manabu Morita, Kazuhide Yamamoto, Hiroyuki Okada
Objective Oxidative stress is associated with the progression of chronic liver disease. Non-alcoholic fatty liver disease (NAFLD) is also an oxidative stress-related disease. However, the oxidative/anti-oxidative balance has not been fully characterized in NAFLD. The objective of the present study was to investigate the balance between oxidative stress and the anti-oxidative activity in NAFLD, including non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC). Patients We recruited 69 patients with histologically proven NAFLD without HCC (NAFLD; n=58), and with NASH-related HCC (NASH-HCC; n=11)...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28124012/liraglutide-s-use-in-treatment-of-non-alcoholic-fatty-liver-an-evaluation-of-the-non-alcoholic-steatohepatitis-study
#11
COMMENT
Debra A Guss, Smruti R Mohanty
No abstract text is available yet for this article.
December 2016: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28116801/assessment-of-treatment-response-in-non-alcoholic-steatohepatitis-using-advanced-magnetic-resonance-imaging
#12
S C Lin, E Heba, R Bettencourt, G Y Lin, M A Valasek, O Lunde, G Hamilton, C B Sirlin, R Loomba
BACKGROUND: Magnetic resonance imaging-derived measures of liver fat and volume are emerging as accurate, non-invasive imaging biomarkers in non-alcoholic steatohepatitis (NASH). Little is known about these measures in relation to histology longitudinally. AIM: To examine any relationship between MRI-derived proton-density fat-fraction (PDFF), total liver volume (TLV), total liver fat index (TLFI), vs. histology in a NASH trial. METHODS: This is a secondary analysis of a 24-week randomised, double-blind, placebo-controlled trial of 50 patients with biopsy-proven NASH randomised to oral ezetimibe 10 mg daily (n = 25) vs...
January 24, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28112179/dicer1-mir-29-hmgcr-axis-contributes-to-hepatic-free-cholesterol-accumulation-in-mouse-non-alcoholic-steatohepatitis
#13
Ming-Xia Liu, Man Gao, Chun-Zhu Li, Cun-Zhi Yu, Hong Yan, Chun Peng, Yu Li, Cheng-Gang Li, Ze-Long Ma, Yang Zhao, Meng-Fan Pu, Ling-Ling Miao, Xin-Ming Qi, Jin Ren
Dicer1 is an enzyme essential for microRNA (miRNA) maturation. The loss of miRNAs resulted from Dicer1 deficiency greatly contributes to the progression of many diseases, including lipid dysregulation, but its role in hepatic accumulation of free cholesterol (FC) that is critical in the development of non-alcoholic steatohepatitis (NASH) remains elusive. In this study, we used the liver-specific Dicer1-knockout mice to identify the miRNAs involved in hepatic FC accumulation. In a widely used dietary NASH model, mice were fed a methionine-choline-deficient (MCD) diet for 3 weeks, which resulted in significant increase in hepatic FC levels as well as decrease of Dicer1 mRNA levels in livers...
January 23, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28110193/effects-of-polyphenol-compounds-melanin-on-nafld-nash-prevention
#14
Natalia Belemets, Nazarii Kobyliak, Oleksandr Virchenko, Tetyana Falalyeyeva, Tsyryuk Olena, Petro Bodnar, Oleksiy Savchuk, Tetyana Galenova, Martin Caprnda, Luis Rodrigo, Lubomir Skladany, Delian Delev, Radka Opatrilova, Peter Kruzliak, Tetyana Beregova, Lyudmyla Ostapchenko
BACKGROUND: One of the pathogenic mechanisms of the progression non-alcoholic liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) is the accumulation of reactive oxygen species (ROS). So, antioxidant therapy is necessary for successful treatment of the liver injury. We have paid attention to melanin produced by yeast Nadsoniella nigra strain X-1 as novel antioxidant and anti-inflammatory agents with low toxicity. In current study we aimed to investigate the preventive effect of melanin on the monosodium glutamate (MSG) induced NAFLD model in rats...
January 19, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28110063/curcumin-ameliorates-liver-damage-and-progression-of-nash-in-nash-hcc-mouse-model-possibly-by-modulating-hmgb1-nf-%C3%AE%C2%BAb-translocation
#15
Rejina Afrin, Somasundaram Arumugam, Azizur Rahman, Mir Imam Ibne Wahed, Vengadeshprabhu Karuppagounder, Meilei Harima, Hiroshi Suzuki, Shizuka Miyashita, Kenji Suzuki, Hiroyuki Yoneyama, Kazuyuki Ueno, Kenichi Watanabe
Curcumin, a phenolic compound, has a wide spectrum of therapeutic effects such as antitumor, anti-inflammatory, anti-cancer and so on. The study aimed to investigate the underlying mechanisms of curcumin to protect liver damage and progression of non-alcoholic steatohepatitis (NASH) in a novel NASH-hepatocellular carcinoma (HCC) mouse model. To induce this model neonatal C57BL/6J male mice were exposed to low-dose streptozotocin and were fed a high-fat diet (HFD) from the age of 4weeks to 14weeks. Curcumin was given at 100mg/kg dose daily by oral gavage started at the age of 10weeks and continued until 14weeks along with HFD feeding...
January 18, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28104990/sitagliptin-in-patients-with-non-alcoholic-steatohepatitis-a-randomized-placebo-controlled-trial
#16
Tisha R Joy, Charles A McKenzie, Rommel G Tirona, Kelly Summers, Shannon Seney, Subrata Chakrabarti, Neel Malhotra, Melanie D Beaton
AIM: To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of non-alcoholic steatohepatitis (NASH). METHODS: Twelve patients with biopsy-proven NASH were randomized to sitagliptin (100 mg daily) (n = 6) or placebo (n = 6) for 24 wk. The primary outcome was improvement in liver fibrosis after 24 wk. Secondary outcomes included evaluation of changes in NAFLD activity score (NAS), individual components of NAS (hepatocyte ballooning, lobular inflammation, and steatosis), glycemic control and insulin resistance [including measurements of glycated hemoglobin (HbA1C) and adipocytokines], lipid profile including free fatty acids, adipose distribution measured using magnetic resonance imaging (MRI), and thrombosis markers (platelet aggregation and plasminogen activator inhibitor 1 levels)...
January 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28100771/janus-kinase-2-jak2-dissociates-hepatosteatosis-from-hepatocellular-carcinoma-in-mice
#17
Sally Yu Shi, Stephanie A Schroer, Cynthia T Luk, Min Jeong Kim, David W Dodington, Lauren Lin, Tharini Sivasubramaniyam, Erica P Cai, Shun-Yan Lu, Kay-Uwe Wagner, Richard P Bazinet, Minna Woo
Hepatocellular carcinoma (HCC) is an end-stage complication of non-alcoholic fatty liver disease (NAFLD). Inflammation plays a critical role in the progression of non-alcoholic fatty liver disease and the development of hepatocellular carcinoma. However, whether steatosis per se promotes liver cancer and the molecular mechanisms that control the progression in this disease spectrum remain largely elusive. The Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway mediates signal transduction by numerous cytokines that regulate inflammation and may contribute to hepatocarcinogenesis...
January 18, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28088461/changes-in-the-prevalence-of-hepatitis-c-virus-infection-non-alcoholic-steatohepatitis-and-alcoholic-liver-disease-among-patients-with-cirrhosis-or-liver-failure-on-the-waitlist-for-liver-transplantation
#18
David Goldberg, Ivo C Ditah, Kia Saeian, Mona Lalehzari, Andrew Aronsohn, Emmanuel C Gorospe, Michael Charlton
BACKGROUND & AIMS: Concurrent to development of more effective drugs for treatment of hepatitis C virus (HCV), infection, there has been an increase in the incidence of non-alcoholic fatty liver disease (NAFLD). Data indicate that liver transplantation prolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD). We compared data on disease prevalence in the population with data from liver transplantation waitlists to evaluate changes in the burden of liver disease in the United States...
January 11, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28077274/the-role-and-regulation-of-the-peroxisome-proliferator-activated-receptor-alpha-in-human-liver
#19
REVIEW
Sander Kersten, Rinke Stienstra
The peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor that is abundantly expressed in liver. PPARα is activated by fatty acids and various other lipid species, as well as by a class of chemicals referred to as peroxisome proliferators. Studies in mice have shown that PPARα serves as the master regulator of hepatic lipid metabolism during fasting. In addition, PPARα suppresses inflammation and the acute phase response. Comparatively little is known about PPARα in human liver...
January 7, 2017: Biochimie
https://www.readbyqxmd.com/read/28076416/the-ccr2-inhibitor-propagermanium-attenuates-diet-induced-insulin-resistance-adipose-tissue-inflammation-and-non-alcoholic-steatohepatitis
#20
Petra Mulder, Anita M van den Hoek, Robert Kleemann
BACKGROUND AND AIM: Obese patients with chronic inflammation in white adipose tissue (WAT) have an increased risk of developing non-alcoholic steatohepatitis (NASH). The C-C chemokine receptor-2 (CCR2) has a crucial role in the recruitment of immune cells to WAT and liver, thereby promoting the inflammatory component of the disease. Herein, we examined whether intervention with propagermanium, an inhibitor of CCR2, would attenuate tissue inflammation and NASH development. METHODS: Male C57BL/6J mice received a high-fat diet (HFD) for 0, 6, 12 and 24 weeks to characterize the development of early disease symptoms of NASH, i...
2017: PloS One
keyword
keyword
82832
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"